DK3096798T3 - Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem - Google Patents

Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem Download PDF

Info

Publication number
DK3096798T3
DK3096798T3 DK15740774.3T DK15740774T DK3096798T3 DK 3096798 T3 DK3096798 T3 DK 3096798T3 DK 15740774 T DK15740774 T DK 15740774T DK 3096798 T3 DK3096798 T3 DK 3096798T3
Authority
DK
Denmark
Prior art keywords
callic
angioedem
hereditary
plasma
treatment
Prior art date
Application number
DK15740774.3T
Other languages
Danish (da)
English (en)
Inventor
Yung Chyung
Daniel J Sexton
Christopher Tenhoor
Jon A Kenniston
Joseph Biedenkapp
Burt Adelman
Ryan Iarrobino
Ryan Faucette
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DK3096798T3 publication Critical patent/DK3096798T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
    • C12Y207/03002—Creatine kinase (2.7.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK15740774.3T 2014-01-21 2015-01-21 Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem DK3096798T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461929716P 2014-01-21 2014-01-21
US201461944361P 2014-02-25 2014-02-25
US201462021397P 2014-07-07 2014-07-07
PCT/US2015/012212 WO2015112578A1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Publications (1)

Publication Number Publication Date
DK3096798T3 true DK3096798T3 (da) 2021-03-01

Family

ID=53681890

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15740774.3T DK3096798T3 (da) 2014-01-21 2015-01-21 Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem

Country Status (18)

Country Link
US (2) US11084884B2 (enExample)
EP (2) EP3848057B1 (enExample)
JP (4) JP6845012B2 (enExample)
KR (4) KR20240049627A (enExample)
CN (2) CN116585468A (enExample)
AU (3) AU2015209481C1 (enExample)
BR (1) BR112016016916B1 (enExample)
CA (1) CA2937329C (enExample)
DK (1) DK3096798T3 (enExample)
EA (1) EA038532B1 (enExample)
ES (1) ES2856076T3 (enExample)
IL (3) IL246864B (enExample)
MX (2) MX387753B (enExample)
NZ (2) NZ761006A (enExample)
PL (1) PL3096798T3 (enExample)
PT (1) PT3096798T (enExample)
WO (1) WO2015112578A1 (enExample)
ZA (2) ZA201605342B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220107T1 (hr) 2010-01-06 2022-04-15 Takeda Pharmaceutical Company Limited Proteini koji vežu kalikrein plazme
CN105713092B (zh) * 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
ES2692408T3 (es) 2013-01-20 2018-12-03 Dyax Corp. Evaluación y tratamiento de trastornos mediados por bradiquinina
IL292121B2 (en) 2013-03-15 2024-02-01 Takeda Pharmaceuticals Co Anti-plasma kallikrein antibodies
IL289514B2 (en) 2013-10-21 2024-01-01 Takeda Pharmaceuticals Co Assays for determining plasma kallikrein system biomarkers
ES2873204T3 (es) 2013-10-21 2021-11-03 Takeda Pharmaceuticals Co Diagnóstico y tratamiento de enfermedades autoinmunes
PT3096798T (pt) * 2014-01-21 2021-02-25 Dyax Corp Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
CN107614532A (zh) * 2015-03-30 2018-01-19 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
MX2018004763A (es) * 2015-10-19 2018-09-06 Dyax Corp Inmunoensayo para detectar quininogeno escindido de alto peso molecular.
KR20250139401A (ko) * 2015-12-11 2025-09-23 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
EP3513196A1 (en) * 2016-09-16 2019-07-24 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system
CN117187377A (zh) 2016-09-16 2023-12-08 武田药品工业株式会社 用于遗传性血管性水肿的rna生物标记
WO2019079496A2 (en) * 2017-10-18 2019-04-25 Regenxbio, Inc. FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION
KR102756073B1 (ko) 2017-12-01 2025-01-20 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 이중-가닥 올리고뉴클레오티드, 조성물 및 이중-가닥 올리고뉴클레오티드를 포함하는 접합체, 그의 제조 방법 및 그의 용도
WO2019105419A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7261494B2 (ja) 2017-12-01 2023-04-20 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
WO2019105435A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
HRP20250408T1 (hr) 2017-12-29 2025-06-06 Suzhou Ribo Life Science Co., Ltd. Kojugati i njihova priprema i uporaba
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
AU2020237259A1 (en) * 2019-03-14 2021-10-14 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP7614650B2 (ja) * 2019-05-24 2025-01-16 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体並びに調製方法と使用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0296171A4 (en) 1986-03-03 1989-11-07 Brigham & Womens Hospital ASSESSMENT PROCEDURE FOR NEPHROTOXICITY.
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
ES2528254T3 (es) 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
US20070253949A1 (en) 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
SI2374472T1 (sl) 2006-03-16 2018-11-30 Dyax Corp., Sestavki in postopki za zdravljenje oftalmoloških motenj
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
US8501695B2 (en) * 2007-07-20 2013-08-06 Diamedica, Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
CA2695012A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2009266856A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc IL6 immunotherapeutics
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
HRP20220107T1 (hr) 2010-01-06 2022-04-15 Takeda Pharmaceutical Company Limited Proteini koji vežu kalikrein plazme
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
KR102136208B1 (ko) 2011-05-02 2020-07-21 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
KR102419640B1 (ko) 2013-01-20 2022-07-12 다케다 파머수티컬 컴패니 리미티드 pKal 매개 장애의 평가, 검정 및 치료
ES2692408T3 (es) 2013-01-20 2018-12-03 Dyax Corp. Evaluación y tratamiento de trastornos mediados por bradiquinina
IL292121B2 (en) 2013-03-15 2024-02-01 Takeda Pharmaceuticals Co Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
IL289514B2 (en) 2013-10-21 2024-01-01 Takeda Pharmaceuticals Co Assays for determining plasma kallikrein system biomarkers
PT3096798T (pt) * 2014-01-21 2021-02-25 Dyax Corp Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
CN107614532A (zh) 2015-03-30 2018-01-19 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途
KR20250139401A (ko) 2015-12-11 2025-09-23 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
CN109716137B (zh) * 2016-09-16 2023-07-21 武田药品工业株式会社 用于与接触活化系统相关的疾病的代谢产物生物标记
EP3678553B1 (en) 2017-09-05 2024-05-22 Sanolla Ltd Diagnosis of pathologies using infrasonic signatures
JP7585193B2 (ja) 2018-08-30 2024-11-18 武田薬品工業株式会社 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
AU2020237259A1 (en) 2019-03-14 2021-10-14 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Also Published As

Publication number Publication date
KR20240049627A (ko) 2024-04-16
CA2937329A1 (en) 2015-07-30
AU2015209481C1 (en) 2020-10-29
EP3848057A1 (en) 2021-07-14
AU2015209481B2 (en) 2020-07-30
ES2856076T3 (es) 2021-09-27
ZA201605342B (en) 2020-11-25
IL263669A (en) 2019-01-31
AU2020244370A1 (en) 2020-10-29
JP2017503820A (ja) 2017-02-02
EP3096798A1 (en) 2016-11-30
IL278062B (en) 2022-06-01
EA201691470A1 (ru) 2016-12-30
AU2015209481A1 (en) 2016-08-25
BR112016016916A8 (pt) 2018-05-02
JP2023015087A (ja) 2023-01-31
AU2020244370B2 (en) 2024-03-07
KR20160122169A (ko) 2016-10-21
NZ761006A (en) 2023-04-28
MX2016009428A (es) 2017-04-13
CA2937329C (en) 2022-05-31
IL263669B (en) 2020-10-29
BR112016016916A2 (pt) 2018-01-23
KR102424183B1 (ko) 2022-07-26
PL3096798T3 (pl) 2021-07-26
ZA202004653B (en) 2022-01-26
CN106132442A (zh) 2016-11-16
IL278062A (en) 2020-11-30
AU2024203436A1 (en) 2024-06-13
EP3848057B1 (en) 2025-12-10
BR112016016916B1 (pt) 2023-12-19
CN116585468A (zh) 2023-08-15
IL246864B (en) 2018-12-31
JP2020002171A (ja) 2020-01-09
EP3096798B1 (en) 2020-11-25
NZ723369A (en) 2022-12-23
US12384854B2 (en) 2025-08-12
KR20220107077A (ko) 2022-08-01
PT3096798T (pt) 2021-02-25
US20210087293A1 (en) 2021-03-25
EP3096798A4 (en) 2017-08-23
JP2024170495A (ja) 2024-12-10
JP6845012B2 (ja) 2021-03-17
KR20240033156A (ko) 2024-03-12
US20170002094A1 (en) 2017-01-05
JP7164502B2 (ja) 2022-11-01
CN106132442B (zh) 2023-07-14
MX387753B (es) 2025-03-18
MX2021013665A (es) 2021-12-10
US11084884B2 (en) 2021-08-10
EA038532B1 (ru) 2021-09-10
WO2015112578A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
IL282704A (en) De novo binding domain containing polypeptides and uses thereof
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3201336T3 (da) Fremgangsmåder til ekstrahering og oprensning af ikke-denaturerede proteiner
IL246921B (en) Binding proteins and methods of use thereof
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3350201T3 (da) Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3524255T3 (da) Sammensætning til behandling af acne
DK3127923T3 (da) Fremgangsmåde til forbedring af oppløselighed af protein og peptid ved hjælp af immunoglobulin-fc-fragment-binding